Vivos Therapeutics (VVOS) Current Assets (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Current Assets data on file, last reported at $4.8 million in Q1 2026.

• Current Assets for Q1 2026 came in at $4.8 million, up 33.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (up 33.6% YoY), and the FY2025 annual result was $4.4 million, down 41.34% from the prior year.
• Current Assets grew to $4.8 million in Q1 2026 per VVOS's latest filing, from $4.4 million in the prior quarter.
• Over five years, Current Assets peaked at $21.6 million in Q1 2022 and troughed at $2.0 million in Q3 2023.
• A 5-year average of $7.2 million and a median of $5.8 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2024: Current Assets sank 80.15% in 2022, then soared 272.75% in 2024.
• A 5-year view of Current Assets shows it stood at $5.4 million in 2022, then slumped by 54.63% to $2.5 million in 2023, then surged by 203.66% to $7.5 million in 2024, then slumped by 41.34% to $4.4 million in 2025, then increased by 9.92% to $4.8 million in 2026.
• Business Quant data shows VVOS's Current Assets at $4.8 million in Q1 2026, $4.4 million in Q4 2025, and $5.8 million in Q3 2025.